IDKmonitor® Infliximab Total ADA ELISA
Available with Lead Time!
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 25 µl
Incubation time: 3h
Size: 96 wells
Regulatory Status: For research use only in the U.S.
Kit Manual: Download
The IDKmonitor® Infliximab Total ADA ELISA is intended for the determination of human antibodies against TNF-alpha blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.
For research use only. Not for use in diagnostic procedures.
For Laboratory Professional Use Only.
This is the RUO version of Immundiagnostik part number K 9654.
Test Principle of the IDKmonitor® Infliximab Total ADA ELISA
This ELISA is used for the determination of antibodies against TNFα-Blocker infliximab (e. g. REMICADE®).
During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody in order to acquire free ADA. By adding the conjugate (peroxidase-labeled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product.
The enzymatic reaction is stopped by adding an acidic solution. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.
|6.5 × 10 × 4.5 in